Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
复制标题
DOI：
10.1097/hjh.0000000000002450
复制
发表时间：
2020-05-01
影响因子：
4.9
通讯作者：
Esler, Danielle
中科院分区：
文献类型：
--
作者：
Esler, Murray;Esler, Danielle
引起新冠肺炎大流行的新型冠状病毒SARS-CoV-2在与膜血管紧张素转换酶2结合后进入肺细胞[1]。这种酶是ACE1的同系物，它将血管紧张素I转化为血管紧张素II，在心血管控制中活跃，可以是心血管疾病的一个元素，并使用ACE1抑制剂如依那普利和赖诺普利治疗高血压和心力衰竭。ACE2的生物学和治疗潜力尚不清楚。通常，在心血管领域，它被认为在某种程度上拮抗ACE1的不利影响，并有益。这一点仍然没有得到很好的解决，目前还没有涉及ACE2的特定心血管疗法。血管紧张素转换酶2的作用之一是将血管紧张素II酶切成血管紧张素(1-7)。
The novel coronavirus causing the COVID-19 pandemic, SARS-CoV-2, gains entry to pulmonary cells after binding to membrane ACE2 [1]. This enzyme is a homologue of ACE1, which converts angiotensin I to angiotensin II, is active in cardiovascular control, can be an element in cardiovascular disease, and is therapeutically targeted in hypertension and heart failure, using ACE1 inhibitors such as enalapril and lisinopril.The biology and therapeutic potential of ACE2 is much less clear. Commonly, it is viewed in the cardiovascular sphere as somehow antagonistic to the adverse effects of ACE1, and beneficial. This remains not well worked out, and currently there are no specific cardiovascular therapies involving ACE2. One action of ACE2 is to enzymatically cleave angiotensin II to angiotensin (1–7).